MedTrace Logo

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

NCT06250283 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-05-13

No results posted yet for this study

Summary

The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.

Conditions

  • Low Bone Mass

Interventions

DIETARY_SUPPLEMENT

Resveratrol

Resveratrol (500 mg)

DIETARY_SUPPLEMENT

Placebo

Placebo (500 mg)

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • University of Delaware

    lead OTHER

Principal Investigators

  • Sheau Ching Chai, PhD, RD · University of Delaware

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2025-10-30
Completion
2026-01-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06250283 on ClinicalTrials.gov